Form 4: EXAS CEO Conroy Reports Routine Stock Transactions

Exact Sciences CEO Kevin T. Conroy reported the vesting of restricted stock units, related tax withholding, and a new RSU grant.

Summary

• CEO Kevin T. Conroy acquired 13,181 shares of common stock upon the vesting of a restricted stock unit (RSU) award.
• 6,196 shares of common stock were disposed of by the Issuer for tax withholding purposes at a price of $103.45 per share, in connection with the net-settlement of RSU vesting.
• A new grant of 154,829 Restricted Stock Units was reported, with these units vesting in four equal annual installments beginning on February 25, 2027.
• Following these transactions, Mr. Conroy's direct beneficial ownership of common stock is 1,241,955 shares.
• Indirect beneficial ownership includes 29,051 shares in a 401(k) Plan and 250,715 shares across three Grantor Retained Annuity Trusts (46,538, 86,750, and 117,427 shares respectively).
• The total common stock reported on this Form 4 is 1,521,721 shares, in addition to 805,226 vested and unvested options and restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, reflecting routine executive compensation activities without indicating any significant positive or negative operational or financial developments for the company.

Positives

• The vesting of 13,181 restricted stock units represents a realization of compensation for the CEO.
• A new grant of 154,829 Restricted Stock Units indicates continued long-term incentive and alignment of management interests with shareholder value.

Future Outlook

The new grant of 154,829 Restricted Stock Units, which vest in four equal annual installments beginning on February 25, 2027, indicates a continued long-term incentive structure for the CEO.

Industry Context

StockSavvy.ai notes that routine insider transactions like RSU vesting, associated tax-related sales, and new RSU grants are common components of executive compensation packages across the biotech and diagnostics industry. These transactions typically reflect standard incentive structures rather than a change in strategic direction or immediate operational performance.

Comparison to Industry Standards

• The nature of these transactions (RSU vesting, tax withholding, new RSU grants) aligns with standard executive compensation practices observed in publicly traded companies, particularly within the healthcare and technology sectors.
• The vesting schedule for the new RSU grant (four equal annual installments) is a common approach to incentivize long-term executive retention and performance, comparable to practices at companies like Illumina or Guardant Health in the diagnostics space.

Related Party Transactions

• The reported transactions involve the CEO and the company, which are standard related-party dealings for executive compensation.

Stakeholder Impact

• Shareholders: The vesting of restricted stock units and new grants represent a form of equity compensation, which can lead to minor dilution but is a standard practice for incentivizing management.

Next Steps

• The newly granted 154,829 Restricted Stock Units will vest in four equal annual installments, with the first installment occurring on February 25, 2027.

Key Dates

Recommendation

This Form 4 filing details routine compensation-related stock transactions for the CEO, including RSU vesting, tax withholding, and a new RSU grant. Such transactions are standard and do not typically signal a change in the company's fundamental outlook or performance, thus warranting a 'hold' recommendation based solely on this filing.

Keywords

EXAS, Exact Sciences, Kevin T. Conroy, Form 4, insider trading, stock transactions, RSU, restricted stock units, CEO, director, compensation